Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Ultragenyx Pharmaceutical : to Present at Jefferies Gene Therapy Summit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/27/2018 | 07:05am EDT

(GlobeNewswire) - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company`s Chief Executive Officer, will present at the Jefferies Gene Therapy Summit on Thursday, September 27, 2018 at 8:00am ET in New York.

The live and archived webcast of the company presentation will be accessible from the companys website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyxs strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the Company`s website at www.ultragenyx.com.

Contact Ultragenyx Pharmaceutical Inc.Investors & MediaDanielle Keatley 415-475-6876

(c) 2018 Future Publishing Limited Quay House, The Ambury, Bath BA1 1UA. All rights reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
06/20ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
06/19Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration a..
GL
06/17ULTRAGENYX PHARMACEUTICAL INC. : Submission of Matters to a Vote of Security Hol..
AQ
06/17Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commerci..
GL
05/31Ultragenyx to Present at Upcoming Investor Conferences
GL
05/30ULTRAGENYX PHARMACEUTICAL : Announces Emil D. Kakkis, M.D., Ph.D. as Recipient o..
AQ
05/29Ultragenyx Announces Emil D. Kakkis, M.D., Ph.D. as Recipient of BIO's 2019 H..
GL
05/10ULTRAGENYX PHARMACEUTICAL : to Present at Bank of America Merrill Lynch Healthca..
AQ
05/07ULTRAGENYX PHARMACEUTICAL : Management's Discussion and Analysis of Financial Co..
AQ
05/06ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, ..
AQ
More news
Financials ($)
Sales 2019 98,1 M
EBIT 2019 -384 M
Net income 2019 -374 M
Finance 2019 355 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 31,2x
EV / Sales 2020 14,6x
Capitalization 3 421 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 75,5 $
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC36.75%3 421
GILEAD SCIENCES9.48%87 076
VERTEX PHARMACEUTICALS8.71%46 140
REGENERON PHARMACEUTICALS-16.20%33 708
GENMAB11.33%11 177
ARRAY BIOPHARMA INC224.42%10 247